Literature DB >> 20703861

Correlation between glucose transporter-1 expression and 18F-fluoro-2-deoxyglucose uptake on positron emission tomography in lung cancer.

Katsuo Usuda1, Motoyasu Sagawa, Hirokazu Aikawa, Masakatsu Ueno, Makoto Tanaka, Yuichiro Machida, Xi-Tong Zhao, Yoshimichi Ueda, Koutaro Higashi, Tsutomu Sakuma.   

Abstract

PURPOSE: The aim of this study was to determine if glucose transporter-1 (Glut1) expression correlates with (18)F-FDG ((18)F-fluoro-2-deoxyglucose) uptake on positron emission tomography (PET) in lung cancer and to examine the similarities and differences between them.
METHODS: A total of 34 patients with resected primary lung cancers were investigated in this study. There were 17 adenocarcinomas, 12 squamous cell carcinomas, and 5 cancers of other cell types. Immunohistochemical Glut1 intensity was categorized into three groups: negative, positive, and strongly positive. Glut1 frequency was defined by the proportion of positive cells among all cancer cells, and it was graded on a semiquantitative scale as 0-100% in 10% increments. The data are expressed as the mean +/- SD.
RESULTS: Maximum standardized uptake values (SUVmax) were 4.8 +/- 6.3 in "negative" Glut1 intensity cases, 4.7 +/- 3.1 in "positive" Glut1 intensity cases, and 11.2 +/- 5.2 in "strongly positive" Glut1 intensity cases. Although SUVmax correlated significantly with tumor size (correlation coefficient 0.58, P = 0.00033), Glut1 frequency did not correlate significantly with tumor size (correlation coefficient 0.18, P = 0.301). Cell type and cell differentiation correlated significantly with Glut1 expression and (18)F-FDG uptake.
CONCLUSION: Glut1 expression correlates significantly with (18)F-FDG uptake. There are similarities in cell differentiation and cell type between Glut1 expression and (18)F-FDG uptake. (18)F-FDG uptake correlates significantly with tumor size, but Glut1 expression does not.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20703861     DOI: 10.1007/s11748-010-0603-1

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  14 in total

1.  Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.

Authors:  Suzanne L Aquino; Jane C Asmuth; Nathaniel M Alpert; Elkan F Halpern; Alan J Fischman
Journal:  J Comput Assist Tomogr       Date:  2003 Jul-Aug       Impact factor: 1.826

2.  [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.

Authors:  Marcelo Mamede; Tatsuya Higashi; Masanori Kitaichi; Koichi Ishizu; Takayoshi Ishimori; Yuji Nakamoto; Kazuhiro Yanagihara; Mio Li; Fumihiro Tanaka; Hiromi Wada; Toshiaki Manabe; Tsuneo Saga
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

3.  Differential diagnosis of lung tumor with positron emission tomography: a prospective study.

Authors:  K Kubota; T Matsuzawa; T Fujiwara; M Ito; J Hatazawa; K Ishiwata; R Iwata; T Ido
Journal:  J Nucl Med       Date:  1990-12       Impact factor: 10.057

4.  Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer.

Authors:  R S Brown; J Y Leung; P V Kison; K R Zasadny; A Flint; R L Wahl
Journal:  J Nucl Med       Date:  1999-04       Impact factor: 10.057

5.  Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

Authors:  N Avril; M Menzel; J Dose; M Schelling; W Weber; F Jänicke; W Nathrath; M Schwaiger
Journal:  J Nucl Med       Date:  2001-01       Impact factor: 10.057

6.  Accuracy of PET/CT in characterization of solitary pulmonary lesions.

Authors:  Shanna K Kim; Martin Allen-Auerbach; Jonathan Goldin; Barbara J Fueger; Magnus Dahlbom; Matthew Brown; Johannes Czernin; Christiaan Schiepers
Journal:  J Nucl Med       Date:  2007-02       Impact factor: 10.057

Review 7.  From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.

Authors:  K Kubota
Journal:  Ann Nucl Med       Date:  2001-12       Impact factor: 2.668

8.  Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma.

Authors:  K Higashi; Y Ueda; H Seki; K Yuasa; M Oguchi; T Noguchi; M Taniguchi; H Tonami; T Okimura; I Yamamoto
Journal:  J Nucl Med       Date:  1998-06       Impact factor: 10.057

9.  Correlation of Glut-1 glucose transporter expression with [(18)F]FDG uptake in non-small cell lung cancer.

Authors:  K Higashi; Y Ueda; A Sakurai; X Mingwang; L Xu; M Murakami; H Seki; M Oguchi; S Taki; Y Nambu; H Tonami; S Katsuda; I Yamamoto
Journal:  Eur J Nucl Med       Date:  2000-12

10.  Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging.

Authors:  Jin-Haeng Chung; Kyung-Ja Cho; Seung-Sook Lee; Hee Jong Baek; Jong-Ho Park; Gi Jeong Cheon; Chang-Woon Choi; Sang Moo Lim
Journal:  J Nucl Med       Date:  2004-06       Impact factor: 10.057

View more
  13 in total

1.  NF-κB protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: a radiogenomics validation study to understand tumor metabolism.

Authors:  Viswam S Nair; Olivier Gevaert; Guido Davidzon; Sylvia K Plevritis; Robert West
Journal:  Lung Cancer       Date:  2013-11-13       Impact factor: 5.705

2.  A systemic review of PET and biology in lung cancer.

Authors:  Kyoichi Kaira; Noboru Oriuchi; Noriaki Sunaga; Tamotsu Ishizuka; Kimihiro Shimizu; Nobuyuki Yamamoto
Journal:  Am J Transl Res       Date:  2011-07-27       Impact factor: 4.060

3.  Relations Between Pathological Markers and Radioiodine Scan and (18)F-FDG PET/CT Findings in Papillary Thyroid Cancer Patients With Recurrent Cervical Nodal Metastases.

Authors:  Jeong Won Lee; Hye Sook Min; Sang Mi Lee; Hyun Woo Kwon; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2015-02-13

4.  ¹⁸F-fluoro-2-deoxyglucose uptake on PET CT and glucose transporter 1 expression in colorectal adenocarcinoma.

Authors:  Ran Hong; Sung-Chul Lim
Journal:  World J Gastroenterol       Date:  2012-01-14       Impact factor: 5.742

5.  GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker.

Authors:  Kátia C Carvalho; Isabela W Cunha; Rafael M Rocha; Fernanda R Ayala; Mariana M Cajaíba; Maria D Begnami; Rafael S Vilela; Geise R Paiva; Rodrigo G Andrade; Fernando A Soares
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

6.  Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder.

Authors:  Henning Reis; Stephan Tschirdewahn; Tibor Szarvas; Herbert Rübben; Kurt Werner Schmid; Florian Grabellus
Journal:  Oncol Lett       Date:  2011-08-29       Impact factor: 2.967

7.  Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.

Authors:  Milica Momcilovic; Sean T Bailey; Jason T Lee; Michael C Fishbein; Clara Magyar; Daniel Braas; Thomas Graeber; Nicholas J Jackson; Johannes Czernin; Ethan Emberley; Matthew Gross; Julie Janes; Andy Mackinnon; Alison Pan; Mirna Rodriguez; Melissa Works; Winter Zhang; Francesco Parlati; Susan Demo; Edward Garon; Kostyantyn Krysan; Tonya C Walser; Steven M Dubinett; Saman Sadeghi; Heather R Christofk; David B Shackelford
Journal:  Cell Rep       Date:  2017-01-17       Impact factor: 9.995

8.  Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD.

Authors:  Cen Zhang; Juan Liu; Rui Wu; Yingjian Liang; Meihua Lin; Jia Liu; Chang S Chan; Wenwei Hu; Zhaohui Feng
Journal:  Oncotarget       Date:  2014-07-30

9.  GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography.

Authors:  Omar Hasan Ali; Stefan Diem; Josef Aschwanden; Eva Markert; Abel-Jan Tasman; Joachim Mueller; Lukas Flatz
Journal:  JAAD Case Rep       Date:  2016-10-13

10.  [18F]Fluorodeoxyglucose accumulation as a biological marker of hypoxic status but not glucose transport ability in gastric cancer.

Authors:  Ryusuke Takebayashi; Kunihiko Izuishi; Yuka Yamamoto; Reiko Kameyama; Hirohito Mori; Tsutomu Masaki; Yasuyuki Suzuki
Journal:  J Exp Clin Cancer Res       Date:  2013-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.